Alexander Edward Perl, MD, MS
Hematologist Oncologist, Associate Professor of Medicine at the Hospital of the University of Pennsylvania
21 years treating Acute Myeloid Leukemia
Dr. Perl specializes in the care of patients with acute leukemia (AML and ALL), myelodysplastic syndromes (MDS), and CML.
Dr. Alexander Perl is a member of the leukemia program in the Abramson Cancer Center and an Associate Professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania. His research focuses on molecularly-targeted therapeutics for acute leukemia. His principal expertise is in FLT3 inhibitors for AML and he has played a leading role in clinical trails of these agents. He also studies other agents targeting signal transduction, such as tyrosine kinase inhibitors for Ph-like ALL and inhibitors of oncogenic PI3K/AKT/mTOR signaling. His laboratory studies focus on phospho-specific flow cytometry of fixed, unfractionated blood and marrow as a method to quantify pharmacodynamic response to signal transduction inhibitors. He is additionally interested in preclinical drug screening in cellular and murine xenotransplantation models of acute leukemia.
University Of Pennsylvania Abramson Cancer Center: Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA